%0 Journal Article
%T PD-L1 inhibitors in the pipeline: Promise and progress
%A Antonio M. Grimaldi
%A Ester Simeone
%A Lucia Festino
%A Martina Strudel
%A Paolo A. Ascierto
%A Vito Vanella
%J Archive of "Oncoimmunology".
%D 2018
%R 10.1080/2162402X.2017.1365209
%X Checkpoint inhibitors have improved survival for patients with melanoma, non-small-cell lung cancer (NSCLC), bladder, head and neck and other cancers. Antibodies against PD-L1, including atezolizumab, avelumab and durvalumab, are also being developed and have been approved for various cancers. Compared with anti-CTLA-4 drugs, studies with anti-PD-1/PD-L1 agents have suggested higher response rates and improved survival. Targeting PD-L1 rather than PD-1 may also theoretically offer further benefit, with the potential for improved efficacy and reduced toxicity, although this has not been clearly shown by clinical experience to date. Anti-PD-L1 agents have shown good efficacy and manageable toxicity in several tumor types
%K Atezolizumab
%K avelumab
%K bladder cancer
%K durvalumab
%K immunotherapy
%K lung cancer
%K melanoma
%K Merkel cell carcinoma
%K PD-L1
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739559/